PD1/VEGF-A BsAbs, ivonescimab, are also being evaluated for making use of chemotherapy to treat EGFR + metastatic NSCLC patients who failed treatments with EGFR inhibitors in a phase III trial [143]. Here, EGFR is linked to non-small cell lung carcinoma.